VictoryShares WestEnd Global Equity ETF GLOW
Set alert
34.20 USD -0.43 -1.25%
At close · Oct 30
34.20 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
34.06 Day range 34.40
29.37 52-week range 35.56
- YTD
- +10.88%
- 1 year
- +11.64%
- Open
- 34.40
- Prev close
- 34.63
- Mkt cap
- 65.95M
- Vol
- 7.90K
- Avg vol
- 11.86K
- EPS
- 1.73
- P/E
- 19.80
- Div yield
- 0.00%
More statistics
- Low
- 34.06
- High
- 34.40
3M chart
Events in this range
- Oct 8, 2026Dividend: 0.007397
Signals (22)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 4 days ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
News
- VictoryShares WestEnd Global Equity ETF (NASDAQ:GLOW) to Issue Monthly Dividend of $0.01
- Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
- Glow Lifetech Grants Stock Options
- Glow Lifetech Reports 238% YoY Revenue Growth and Near-Breakeven EBITDA in Q1 2025, Marking Third Straight Quarter of 40%+ Sequential Revenue Growth
- Glow Lifetech Reports 2024 Financials, Delivering Record Q4 Results with 46% Quarterly Revenue Growth and Strengthened Balance Sheet
- Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
- Glow Lifetech Provides Commercial Update; Continued Growth Momentum with New Product Launch & National Expansion
- Glow LifeTech Announces Appointment of David Côté to Board of Directors
- Glow Lifetech Grants Stock Options
- Glow Lifetech Announces Completion of Final Payment under Swiss Pharma Share Exchange Agreement and Debt Settlement
Your note
Sign in to keep a note on GLOW — it syncs with the Stock Master app.